Entasis Therapeutics (NASDAQ: ETTX) is one of 555 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare Entasis Therapeutics to similar companies based on the strength of its valuation, profitability, dividends, analyst recommendations, risk, institutional ownership and earnings.
Insider and Institutional Ownership
65.6% of Entasis Therapeutics shares are owned by institutional investors. Comparatively, 45.6% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 15.6% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This is a summary of current recommendations for Entasis Therapeutics and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Entasis Therapeutics Competitors||4729||13414||28187||1021||2.54|
Entasis Therapeutics currently has a consensus price target of $18.75, suggesting a potential upside of 182.38%. As a group, “Pharmaceutical preparations” companies have a potential upside of 61.81%. Given Entasis Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Entasis Therapeutics is more favorable than its rivals.
This table compares Entasis Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Entasis Therapeutics Competitors||-1,566.06%||-828.31%||-27.99%|
Earnings and Valuation
This table compares Entasis Therapeutics and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Entasis Therapeutics||$5.00 million||-$32.95 million||-0.54|
|Entasis Therapeutics Competitors||$2.14 billion||$224.95 million||-3.93|
Entasis Therapeutics’ rivals have higher revenue and earnings than Entasis Therapeutics. Entasis Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Entasis Therapeutics beats its rivals on 8 of the 12 factors compared.
About Entasis Therapeutics
Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. Entasis Therapeutics Holdings was founded in March 2018 and is headquartered in Waltham, MA.
Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.